Serum measures of iron status and HFE gene mutations in patients with hepatitis B virus infection

Hepatology Research

Volumn 37, Issue 3, 2007, Pages 172-178

  Ghaziani, Tahereh ^a,b,c   Alavian, Seyed Moayed ^d,e   Zali, Mohammad R ^b   Shahraz, Saeid ^b,f   Agah, Mohammdreza ^b   Jensen, Kevin P ^a   Ansari, Shahin ^b   Sendi, Hossein ^b   Lambrecht, Richard W ^a   Covault, Jonathan ^a   Bonkovsky, Herbert L ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c CAMBRIDGE HOSPITAL   (United States)

^d Tehran Heart Center   (Iran)

^e BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f HARVARD UNIVERSITY   (United States)

Author keywords

Fibrosis; Hepatitis B; HFE; Iran; Serum ferritin; Transferrin saturation

Indexed keywords

FERRITIN; HFE PROTEIN; IRON; TRANSFERRIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HEPATITIS B; HUMAN; IRAN; IRON BLOOD LEVEL; LIVER DISEASE; LIVER FIBROSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRANSFERRIN BLOOD LEVEL; VIRUS CARRIER;

EID: 33947162139     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00026.x     Document Type: Article

References (43)

1. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759-68.
2. Bonkovsky HL. Iron as a comorbid factor in chronic viral hepatitis. Am J Gastroenterol 2002; 97: 1-4.
3. Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 2003; 30: 137-44.
4. Bonkovsky HL, Troy N, McNeal K et al. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 2002; 37: 848-54.
5. Smith BC, Gorve J, Guzail MA et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998; 27: 1695-9.
6. Kazemi-Shirazi L, Datz C, Maier-Dobersberger T et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999; 116: 127-34.
7. Thorburn D, Curry G, Spooner R et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002; 50: 248-52.
8. Bonkovsky HL, Jawaid Q, Tortorelli K et al. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-9.
9. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27: 1661-9.
10. Erhardt A, Maschner-Olberg A, Mellenthin C et al. HFE mutations and chronic hepatitis C. H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 2003; 38: 335-42.
11. Felton C, Lustbader ED, Merten C et al. Serum iron levels and response to hepatitis B virus. Proc Natl Acad Sci USA 1979; 76: 2438-41.
12. Blumberg BS, Lustbader ED, Whitford PL. Changes in serum iron levels due to infection with hepatitis B virus. Proc Natl Acad Sci USA 1981; 78: 3222-4.
13. Bayraktar Y, Koseoglu T, Somner C et al. The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B. J Viral Hepat 1996; 3: 129-35.
14. Bayraktar Y, Saglam F, Temizer A et al. The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B. Hepatogastroenterology 1998; 45: 2322-7.
15. Sendi H, Ghaziani T, Zali MR et al. Hemochromatosis mutations in Iranians with hepatitis B virus infection. Clin Infect Dis 2005; 40: e19-e21.
16. Yamanishi H, Iyama S, Yamaguchi Y et al. Modification of fully automated total iron-binding capacity (TIBC) assay in serum and comparison with dimension TIBC method. Clin Chem 2002; 48: 1565-70.
17. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
18. Liu ZW, Han QY, Zhang N et al. Sequential changes of serum ferritin levels and their clinical significance in lamivudine-treated patients with chronic viral hepatitis B. World J Gastroenterol 2004; 10: 972-6.
19. Piperno A, Vergani A, Malosio I et al. Hepatic iron overload in patients with chronic viral hepatitis: Role of HFE gene mutations. Hepatology 1998; 28: 1105-9.
20. Martinelli AL, Filho AB, Franco RF et al. Liver iron deposits in hepatitis B patients: Association with severity of liver disease but not with hemochromatosis gene mutations. J Gastroenterol Hepatol 2004; 19: 1036-41.
21. Bonkovsky HL, Naishadham D, Lambrecht RW et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006; 131: 1440-51
22. Mah YH, Kao JH, Liu CJ et al. Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan. Liver Int 2005; 25: 214-19.
23. de Sousa M, Porto G. The immunological system in hemochromatosis. J Hepatol 1998; 28 (Suppl 1): 1-7.
24. Arosa FA, Oliveira L, Porto G et al. Anomalies of the CD8+ T cell pool in haemochromatosis: HLA-A3-linked expansions of CD8+. Clin Exp Immunol 1997; 107: 548-54.
25. Bacon BR, Powell LW, Adams PC et al. Molecular medicine and hemochromatosis: At the crossroads. Gastroenterology 1999; 116: 193-207.
26. Jazayeri M, Bakayev V, Adibi P et al. Frequency of HFE gene mutations in Iranian beta-thalassaemia minor patients. Eur J Haematol 2003; 71: 408-11.
27. Bakayev V, Ignatiev I, Jazayeri M et al. Duplex polymerase chain reaction-restriction fragment length polymorphism assay for rapid detection of HFE mutations-C282Y occurs with a low frequency in Tehran's population. J Hepatol 2004; 40: 559-60.
28. Karimi M, Yavarian M, Delbini P et al. Spectrum and haplotypes of the HFE hemochromatosis gene in Iran: H63D in beta-thalassemia major and the first E277K homozygous. Hematol J 2004; 5: 524-7.
29. Lucotte G. Celtic origin of the C282Y mutation of hemochromatosis. Blood Cells Mol Dis 1998; 24: 433-8.
30. Beutler E, Felitti V, Gelbart T et al. Genetics of iron storage and hemochromatosis. Drug Metab Dispos 2001; 29: 495-9.
31. Bulaj ZJ, Ajioka RS, Phillips JD et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000; 343: 1529-35.
32. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004; 350: 2383-97.
33. Zoller H, Koch RO, Theurl I et al. Expression of the duodenal iron transporters divalent-metal transporter 1 and ferroportin 1 in iron deficiency and iron overload. Gastroenterology 2001; 120: 1412-19.
34. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-3.
35. Fleming RE, Ahmann JR, Migas MC et al. Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proc Natl Acad Sci USA 2002; 99: 10653-8.
36. Nicolas G, Viatte L, Lou DQ et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 2003; 34: 97-101.
37. Gordeuk VR, Caleffi A, Corradini E et al. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis 2003; 31: 299-304.
38. Bullen JJ, Rogers HJ, Spalding PB et al. Iron and infection: The heart of the matter. FEMS Immunol Med Microbiol 2005; 43: 325-30.
39. Weinberg ED. The role of iron in cancer. Eur J Cancer Prev 1996; 5: 19-36.
40. Tuomainen TP, Nyyssonen K, Salonen R et al. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1013 eastern Finnish men. Diabetes Care 1997; 20: 426-8.
41. Salonen JT, Tuomainen TP, Nyyssonen K et al. Relation between iron stores and non-insulin dependent diabetes in men: Case-control study. BMJ 1998; 317: 727.
42. Di Bisceglie AM, Bonkovsky HL, Chopra S et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial. Hepatology 2000; 32: 135-8.
43. Fontana RJ, Israel J, LeClair P et al. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial. Hepatology 2000; 31: 730-6.